Trial reportNeurogastroenterology and motility2018
Effects of naloxegol on whole gut transit in opioid-naïve healthy subjects receiving codeine: A randomized, controlled trial.
Trial report in Neurogastroenterology and motility, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Autonomic effects of electroacupuncture in opioid-induced constipation in male rats.Physiological reports · 2025Article
- Pyloric Dysfunction: A Review of the Mechanisms, Diagnosis, and Treatment.Gut and liver · 2025Review
- Pharmacologic treatments for gastroparesis.Pharmacological reviews · 2025Review
- P2Y1 receptor in the colonic submucosa of rats and its association with opioid‑induced constipation.Experimental and therapeutic medicine · 2023Article
- Gastroparesis.Gastroenterology · 2022Review
- Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain.Therapeutic advances in gastroenterology · 2022Review
- New Developments in Prokinetic Therapy for Gastric Motility Disorders.Frontiers in pharmacology · 2021Review
- Impact of Opioid Consumption in Patients With Functional Gastrointestinal Disorders.Frontiers in pharmacology · 2020Article
- A Retrospective Study of Patients Undergoing Radical Cystectomy and Receiving Peri-Operative Naloxegol or Alvimopan: Comparison of Length of Stay.Journal of surgery (New York, N.Y.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNausea, vomiting, and constipation (OIC) are common adverse effects of acute or chronic opioid use. Naloxegol (25 mg) is an approved peripherally active mu-opiate opioid receptor antagonist.
aimTo compare the effects on pan-gut transit of treatment with codeine, naloxegol, or combination in healthy volunteers.
methodsWe conducted a randomized, double-blind, placebo-controlled, single-center, parallel-group study in 72 healthy opioid-naïve adults, randomized to: codeine (30 mg q.i.d.), naloxegol (25 mg daily), codeine and naloxegol, or matching placebo. During 3 days of treatment, we measured gastric emptying (GE) T KEY
resultsParticipants were 59.7% women, median BMI 25.0 kg/m CONCLUSIONS AND INFERENCES: Short-term administration of naloxegol (25 mg) in healthy, opioid-naïve volunteers does not reverse the retardation of gastric, small bowel, or colonic transit induced by acute administration of codeine. Further studies with naloxegol at higher dose are warranted to assess the ability to reverse the retardation of transit caused by acute administration of codeine in opioid-naïve subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.